Drug Profile
Uridine
Alternative Names: POL 255Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Polifarma
- Class Pyrimidine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetic neuropathies; Parkinson's disease
Most Recent Events
- 30 Aug 2002 Polifarma and AMINO have entered into an agreement to co-promote and co-develop uridine worldwide
- 30 Aug 2002 Phase-II clinical trials in Diabetic neuropathies in World (PO)
- 30 Aug 2002 Phase-II clinical trials in Parkinson's disease in World (PO)